NCT05454358 is a Phase 2, PHASE3 clinical trial of Letrozole 2.5mg in Endometrial Cancer, sponsored by Fudan University.

Who is sponsoring NCT05454358?

NCT05454358 is sponsored by Fudan University.

What drugs are being tested in NCT05454358?

Interventions in NCT05454358: Letrozole 2.5mg.

What condition does NCT05454358 study?

NCT05454358 studies Endometrial Cancer.

Is NCT05454358 still recruiting?

NCT05454358 is currently terminated. Last updated 15 December 2025.

Last reviewed 2025-12-15 · How we verify

NCT05454358

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

Terminated Phase 2, PHASE3 Last updated 15 December 2025

What this trial tests

Phase 2, PHASE3 trial testing Letrozole 2.5mg in Endometrial Cancer in 12 participants. Terminated before completion.

Timeline

2 August 2022

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2, PHASE3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	2 August 2022
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	1 location across China

Drugs / interventions tested

Letrozole 2.5mg (letrozole-2-5mg) — full drug profile →

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 80, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim to investigate the effect of Letrozole as maintenance after adjuvant treatment on the prognosis of post-operative endometrial cancer patients with non-specific molecular profile.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Moving into the modern era of molecular classification for endometrial cancer.
Dagher C, Liu YL, Mueller JJ, Weigelt B. · · 2024 · cited 7× · PMID 38100711 · DOI 10.1002/jso.27552
Unsolved Issues in the Integrated Histo-Molecular Classification of Endometrial Carcinoma and Therapeutic Implications.
Kuhn E, Gambini D, Runza L, Ferrero S, et al · · 2024 · cited 4× · PMID 39001520 · DOI 10.3390/cancers16132458

Verify or expand the search:

Other trials of Letrozole 2.5mg

Trials testing the same drug.

NCT07109947 — Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage · NA · recruiting
NCT07285382 — Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced · Phase 2 · recruiting
NCT06143631 — Prescription of Letrozole for Uterine Myoma · Phase 4 · recruiting
NCT06405243 — Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients · Phase 3 · not yet recruiting
NCT06507332 — Combination Letrozole and Clomiphene Citrate Versus Letrozole Alone · NA · unknown

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05454358 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 15 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05454358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing